In NRG-GY018/KEYNOTE-868, KEYTRUDA in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after ...

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

Grade 3-5 adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: ...

Merck's Keytruda now approved by European Commission for new gynecologic cancer indications, expanding its reach in the EU.

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

Findings seen in combination with chemotherapy following surgery in patients with curative intent. HealthDay News — Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in ...

Adding pembrolizumab to modern, high-quality chemoradiotherapy significantly improved overall survival in patients with locally advanced cervical cancer.

The European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck & Co’s anti-PD-1 therapy, ...

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...

The acquisition strengthens Merck's oncology portfolio as the company looks to off the expiration of the patent for ...